問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


MacKay Memorial Hospital (在職)

Division of General Internal Medicine

Division of Cardiovascular Diseases

MacKay Memorial Hospital

Division of General Internal Medicine

Division of Cardiovascular Diseases

更新時間：2023-09-19

侯嘉殷
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

0Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

侯嘉殷

List

20Cases

2010-08-30 - 2012-11-30

Phase III

A Phase III, Prospective, Randomized, Double-Blind, PlaceboControlled Multicenter Study to Evaluate the Efficacy and Safety of MK-6621 in Patients with Atrial Fibrillation

  • Condition/Disease

    Atrial Fibrillation

  • Test Drug

    MK-6621

Participate Sites
16Sites

Terminated16Sites

2009-01-01 - 2013-12-31

Phase III

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects With Acute Coronary Syndrome: Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA•CER)

  • Condition/Disease

    Acute Coronary Symdrome

  • Test Drug

    SCH530348

Participate Sites
13Sites

Terminated13Sites

2009-10-31 - 2013-08-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Terminated12Sites

2009-01-20 - 2010-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2014-05-01 - 2019-03-31

Phase III

A Multicenter, Randomized, Double-blind, Placebo Controlled Phase III Study to Evaluate the Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in Acute Heart Failure Patients

  • Condition/Disease

    Acute Heart Failure Patients

  • Test Drug

    REASANZ

Participate Sites
10Sites

Terminated10Sites

2009-05-01 - 2015-09-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2007-10-15 - 2008-10-14

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Terminated11Sites

2008-10-01 - 2010-12-31

Phase IV

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2013-12-01 - 2019-12-31

Phase III

Phase 3 Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Pf-04950615, In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects

  • Condition/Disease

    Major Cardiovascular Events

  • Test Drug

    PF-04950615

Participate Sites
10Sites

Terminated10Sites

2013-12-01 - 2019-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

1 2
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB